4 insiders reported 9 Form 4 transactions for Quince Therapeutics, Inc. (QNCX) over the past 18 months (most recent 2025-12-29). Recent activity: Benatti Luca (Director) Buy 8,918 shares, Benatti Luca (Director) Sell 50,000 shares, Thye Dirk (CEO and CMO) Sell 739,885 shares, Thye Dirk (CEO and CMO) Buy 739,885 shares, Hannah Brendan (CBO, COO & CCO) Buy 2,271 shares. Source: SEC Form 4.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-29 | Benatti Luca | Director | Buy | 8,918 | $0 |
| 2025-12-29 | Benatti Luca | Director | Sell | 50,000 | $173,500 |
| 2025-12-12 | Thye Dirk | CEO and CMO | Sell | 739,885 | $0 |
| 2025-12-12 | Thye Dirk | CEO and CMO | Buy | 739,885 | $0 |
| 2025-12-08 | Hannah Brendan | CBO, COO & CCO | Buy | 2,271 | $1,249 |
| 2025-12-08 | Hannah Brendan | CBO, COO & CCO | Buy | 25,280 | $23,763 |
| 2025-06-23 | Hannah Brendan | CBO, COO & CCO | Buy | 37,736 | $45,283 |
| 2025-06-23 | Ryan Charles S. | President | Buy | 7,548 | $9,058 |
| 2025-06-23 | Thye Dirk | CEO and CMO | Buy | 150,944 | $181,133 |
Source: SEC Form 4 filings · as of 2025-12-29